ESPR Esperion Therapeutics Inc.

Esperion to Participate in JMP Securities Life Sciences Conference

Esperion to Participate in JMP Securities Life Sciences Conference

ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP Securities Life Sciences Conference on Monday, May 15th, 2023 at 2:00 PM ET.

To register for the live webcast, follow this .

A live audio webcast can be accessed on the investor and media section of the Esperion website at . Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics

At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit and and follow us on Twitter at

Contact:

Corporate Communications

 



EN
01/05/2023

Underlying

ESPREsperion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Esperion Therapeutics Inc.

 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in The 2026 Citizens Life Sciences Conference

Esperion to Participate in The 2026 Citizens Life Sciences Conference ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. About Esperion TherapeuticsEsperion Th...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Mar...

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expir...

February 17, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such ind...

February 11, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcar...

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference – Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q –        – Expects Operating Expenses of Between $210 Million and $2...

January 11, 2026 1 EN
 PRESS RELEASE
Free
ESPR Esperion Therap...

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare...

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference ANN ARBOR, Mich., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at J.P. Morgan’s 44th Annual Healthcare Conference on Wednesday, January 14, 2025. The company’s presentation and participation in a fireside chat will begin at 2:15 p.m. PT/5:15 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be ...

January 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch